Romidepsin
Chronic Disease
University of UtahSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Chronic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Federal University of Paraíba | Phase 4 | BB |
Naltrexone Pfizer | Phase 4 | BB |
CYCLOSPORIN A University of Utah | Phase 2 | B |
Monomethyl Fumarate University of Utah | Phase 2 | B |
LIDOCAINE Norwegian University of Science and Technology | Phase 2 | B |
View all 32 →
Same molecule, other indications
Romidepsin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →